Staurenghi G, Garweg JG, Gerendas BS, et al. - In this investigation involving 671 patients (mean age was 74.6 years), researchers tested the safety and effectiveness of two individualized ranibizumab, an anti-vascular endothelial growth factor antibody fragment specifically designed for ophthalmic use, retreatment schemes in neovascular age-related macular degeneration. Study participants were randomized (1:1) to obtain three initial monthly ranibizumab 0.5 mg injections, then retreatment guided by either best-corrected visual acuity (BCVA) loss (Group I) or BCVA loss and/or signs of disease activity on optical coherence tomography (OCT; Group II). Finally, 305 patients completed 12 months of the study. For both retreatment strategies, ranibizumab treatment resulted in visual and anatomic gains at 12 months, with a trend in favor of OCT-guided vs BCVA loss guided retreatment. There were no new safety signals.